Rein reports early Phase II data for inhaled IPF drug
Rein Therapeutics has reported preliminary blinded 12-week findings from the Phase II RENEW clinical study of its lead drug, LTI-03, for IPF.
The post Rein reports early Phase II data for inhaled IPF drug appeared first on Clinical Trials Arena .